DEF: Xilio Therapeutics Seeks Stockholder Approval for Share Increase and Officer Exculpation

Xilio Therapeutics is asking stockholders to approve increasing authorized common stock and providing officer exculpation at its 2025 annual meeting.

Summary

• Xilio Therapeutics is holding its 2025 annual meeting of stockholders virtually on June 10, 2025.
• Stockholders will vote on the election of three Class I directors, an amendment to increase authorized common stock from 200,000,000 to 600,000,000 shares, an amendment for officer exculpation, and ratification of Ernst & Young LLP as the independent accounting firm.
• The board recommends voting for all director nominees, the share increase amendment, the officer exculpation amendment, and the accounting firm ratification.
• As of April 11, 2025, there were 51,775,395 shares of common stock outstanding and entitled to vote.
• The company is soliciting proxies and providing access to proxy materials online.
• The board of directors believes that it is in our best interests to increase the number of authorized shares of common stock in order to give us greater flexibility in considering and planning for potential business needs.
• The board of directors rationale for recommending this amendment is to balance stockholders interest in accountability with their interest in attracting and retaining the highest quality officers and avoiding litigation abuse resulting from the current disparity that exists in the treatment of directors, who oversee and are ultimately accountable for corporate actions, and the officers who execute those actions on behalf of the board of directors.

Sentiment

Score: 7

Explanation: The document is primarily informational, outlining proposals for stockholder vote. The tone is professional and forward-looking, with a focus on providing flexibility and attracting talent. However, there are potential dilutive effects and risks associated with increasing authorized shares, which tempers the overall sentiment.

Positives

• The proposed increase in authorized shares provides greater flexibility for future financing and strategic opportunities.
• The officer exculpation amendment aims to attract and retain high-quality officers by aligning their liability protection with that of directors.
• The virtual meeting format facilitates stockholder attendance and participation.
• The board of directors believes that the availability of additional authorized shares of our common stock will afford us needed flexibility in acting upon financing transactions to strengthen our financial position and/or engaging in strategic activities without using cash.
• The board of directors believes that limiting concern about personal liability will empower officers to best exercise their business judgment in furtherance of stockholder interests without the distraction of potentially being subject to claims following actions taken in good faith.

Negatives

• Increasing authorized shares could dilute earnings per share and stockholders' equity.
• The availability of additional authorized shares may discourage potential takeover attempts.
• Abstentions and broker non-votes will have the effect of a vote AGAINST Proposal 3.

Risks

• Future sales of substantial amounts of our common stock, or the perception that these sales might occur, could adversely affect the prevailing market price of our common stock or limit our ability to raise additional capital.
• Stockholders should recognize that, as a result of this proposal, they will own a smaller percentage of shares relative to the total authorized shares of the Company than they presently own.

Future Outlook

The company anticipates that it may issue additional shares of common stock in the future in connection with one or more of the following: our equity incentive plans; financing transactions, such as public or private offerings of common stock or convertible securities; licenses, partnerships, collaborations and other similar transactions; strategic investments and transactions; and other corporate purposes that have not yet been identified.

Management Comments

• Thank you for your ongoing support and continued interest in Xilio Therapeutics, Inc.
• Our board of directors believes that it is in our best interests to increase the number of authorized shares of common stock in order to give us greater flexibility in considering and planning for potential business needs.
• Our board of directors rationale for recommending this amendment is to balance stockholders interest in accountability with their interest in attracting and retaining the highest quality officers and avoiding litigation abuse resulting from the current disparity that exists in the treatment of directors, who oversee and are ultimately accountable for corporate actions, and the officers who execute those actions on behalf of the board of directors.

Industry Context

The officer exculpation amendment reflects a broader trend in Delaware law to provide greater protection to corporate officers, aligning with practices at other companies competing for talent.

Comparison to Industry Standards

• Many biotechnology companies are incorporated in Delaware and are likely considering or have already adopted similar officer exculpation provisions.
• Increasing authorized shares is a common practice for companies seeking financial flexibility, but the specific amount varies based on company size and strategic plans.
• Comparable companies such as Legend Biotech Corporation, Fate Therapeutics, Inc., and Akero Therapeutics, Inc. have directors with experience serving on multiple boards, reflecting a common practice in the biotech industry.

Stakeholder Impact

• Stockholders will be impacted by the decisions made regarding the election of directors, the increase in authorized shares, and the officer exculpation amendment.
• Employees may be impacted by the officer exculpation amendment, which aims to attract and retain high-quality officers.
• The company's financial flexibility and strategic opportunities may be impacted by the increase in authorized shares.

Next Steps

• Stockholders need to review the proxy materials and vote on the proposals.
• The company will hold its annual meeting on June 10, 2025, to vote on the proposals.
• The company will file a Current Report on Form 8-K to report final voting results within four business days following the annual meeting.

Key Dates

Keywords

proxy statement, annual meeting, directors, authorized shares, officer exculpation, Ernst & Young, common stock, corporate governance, stockholders